Weight Watchers International, Inc. Aktie News

A redesigned Weight Watchers experience pairs comprehensive GLP-1 support with personalised nutrition, coaching, community support, and cutting-edge technology to help members meet their weight loss goals and achieve results that last A redesigned Weight Watchers experience pairs comprehensive GLP-1 support with personalised nutrition, coaching, community support, and cutting-edge technology to...

A redesigned Weight Watchers experience pairs comprehensive GLP-1 support with personalized nutrition, coaching, community support, and cutting-edge technology to help members meet their weight loss goals and achieve results that last A redesigned Weight Watchers experience pairs comprehensive GLP-1 support with personalized nutrition, coaching, community support, and cutting-edge technology to...

A redesigned Weight Watchers experience pairs comprehensive GLP-1 support with personalised nutrition, coaching, community support, and cutting-edge technology to help members meet their weight loss goals and achieve results that last A redesigned Weight Watchers experience pairs comprehensive GLP-1 support with personalised nutrition, coaching, community support, and cutting-edge technology to...

A redesigned Weight Watchers experience pairs GLP-1 prescriptions with personalized nutrition, coaching, community support, and cutting-edge technology to help members meet their weight loss goals and achieve results that last A redesigned Weight Watchers experience pairs GLP-1 prescriptions with personalized nutrition, coaching, community support, and cutting-edge technology to help members me...

WW International (WW) delivered a strong Q3, exceeding revenue and EBITDA expectations, driven by its Clinical Business. WW faces ongoing challenges, including declining Behavioral subscribers and cautious Q4 guidance, which may keep investors wary until trends improve. Key catalysts ahead include FDA decisions on GLP-1 compounding, expanded insurance coverage, and new partnerships with pharma ...

WeightWatchers' CEO said on Wednesday it plans to sell Novo Nordisk's much-anticipated Wegovy in pill form if it is launched next year in the United States, deepening its tie-up with the Danish obesity drugmaker.

WW International, Inc. ( WW ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants David Helderman - Director of Investor Relations Tara Comonte - President, CEO & Director Felicia DellaFortuna - Chief Financial Officer Jon Volkmann - Chief Operations Officer Conference Call Participants Alex Fuhrman - Lucid Capital Markets, LLC, Research Division Justin Ages - CJS Securities...

End of Period Subscribers of 3.0 million, including Clinical Subscribers of 124 thousand  Total Revenues of $172 million; Clinical Subscription Revenues of $26 million, up 35% year-over-year Net Loss of $58 million; Net Loss Margin of 33.4%; Adjusted EBITDA 1 of $43 million and Adjusted EBITDA Margin 1 of 24.9% Narrowing 2025 Guidance to the higher end of previous ranges for Revenue and Adjuste...